Calidi Biotherapeutics to Showcase Oncology Advancements in Upcoming Investor Webinar

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced an investor webinar scheduled for July 24, 2025. The event will focus on the company's RedTail(TM) platform, a novel approach to treating metastatic tumors through systemically delivered viral therapy. CEO Eric Poma, Ph.D., will lead the discussion, highlighting preclinical data on CLD-401, the company's lead candidate, which has shown promising results in tumor elimination and immune memory activation.

The webinar is a significant opportunity for investors and stakeholders to gain insights into Calidi's progress toward filing an Investigational New Drug (IND) application. The company is also exploring strategic partnerships within the pharmaceutical industry to accelerate the commercialization of its therapies. Attendees will have the chance to participate in a Q&A session following the presentation, offering a deeper understanding of Calidi's innovative approach to oncology treatment. For more information, visit https://ibn.fm/zIp8d.

This event underscores the importance of Calidi's work in advancing cancer treatment options. The RedTail(TM) platform represents a potential breakthrough in how metastatic tumors are treated, offering hope for patients with limited options. The preclinical success of CLD-401 highlights the platform's ability to not only target and eliminate tumors but also to activate the immune system's memory, preventing recurrence. As Calidi moves closer to IND filing and seeks partnerships for commercialization, the biotech community watches closely, recognizing the implications of these advancements for the future of oncology.